Dealing with SLE management: a complex, fast-changing story (AUTO 2026) - May 21, 2026 - Pres time: May 15, 2026; 08:30 AM - 09:00 AM; Location: Forum Hall; "These differences are reflected in clinical response kinetics, which tend to be slower with belimumab (approximately 16 weeks) (11) and faster with anifrolumab (approximately 8 weeks) (12)...In addition to belimumab (14), newer agents such as Voclosporin (15) and Obinutuzumab (16) have demonstrated efficacy in phase III trials...Obinutuzumab, a type II anti-CD20 antibody, has demonstrated enhanced B-cell depletion compared with rituximab and achieved significant improvements in renal response rates in phase III studies...NEJM 2020; 383: 1117-1128 15...Zen M, Gatto M, Doria A. Ann Rheum Dis. 2022 Nov; 81(11):1483-1485"
IO biomarker • CNS Disorders • Glomerulonephritis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Diseases • Nephrology • Systemic Lupus Erythematosus • IFNAR1 • IFNAR2
|